Literature DB >> 28723334

ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia.

Daniel Gaudet1, Daniel A Gipe2, Robert Pordy2, Zahid Ahmad3, Marina Cuchel4, Prediman K Shah5, Kuang-Yuh Chyu5, William J Sasiela2, Kuo-Chen Chan2, Diane Brisson1, Etienne Khoury1, Poulabi Banerjee2, Viktoria Gusarova2, Jesper Gromada2, Neil Stahl2, George D Yancopoulos2, G Kees Hovingh6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28723334     DOI： 10.1056/NEJMc1705994

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  70 in total

Review 1.  Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias.

Authors:  Fabiana Rached; Raul D Santos
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 2.931

2.  Modeling hypercholesterolemia and vascular lipid accumulation in LDL receptor mutant zebrafish.

Authors:  Chao Liu; Young Sook Kim; Jungsu Kim; Jennifer Pattison; Andrés Kamaid; Yury I Miller
Journal:  J Lipid Res       Date:  2017-11-29       Impact factor: 5.922

Review 3.  ANGPLT3 in cardio-metabolic disorders.

Authors:  Xin Su
Journal:  Mol Biol Rep       Date:  2021-03-06       Impact factor: 2.316

Review 4.  Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis.

Authors:  Dirk J Blom; Frederick J Raal; Raul D Santos; A David Marais
Journal:  Curr Atheroscler Rep       Date:  2019-11-19       Impact factor: 5.113

5.  Angiopoietin-like proteins as therapeutic targets for cardiovascular disease: focus on lipid disorders.

Authors:  Marco Bruno Morelli; Christopher Chavez; Gaetano Santulli
Journal:  Expert Opin Ther Targets       Date:  2020-01-15       Impact factor: 6.902

6.  Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.

Authors:  Brian A Ference; John J P Kastelein; Kausik K Ray; Henry N Ginsberg; M John Chapman; Chris J Packard; Ulrich Laufs; Clare Oliver-Williams; Angela M Wood; Adam S Butterworth; Emanuele Di Angelantonio; John Danesh; Stephen J Nicholls; Deepak L Bhatt; Marc S Sabatine; Alberico L Catapano
Journal:  JAMA       Date:  2019-01-29       Impact factor: 56.272

7.  Role of angiopoietin-like protein 3 in sugar-induced dyslipidemia in rhesus macaques: suppression by fish oil or RNAi.

Authors:  Andrew A Butler; James L Graham; Kimber L Stanhope; So Wong; Sarah King; Andrew A Bremer; Ronald M Krauss; James Hamilton; Peter J Havel
Journal:  J Lipid Res       Date:  2020-01-09       Impact factor: 5.922

Review 8.  ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.

Authors:  Ioannis Akoumianakis; Evangelia Zvintzou; Kyriakos Kypreos; Theodosios D Filippatos
Journal:  Curr Atheroscler Rep       Date:  2021-03-10       Impact factor: 5.113

Review 9.  Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding.

Authors:  Allan D Sniderman; Patrick Couture; Seth S Martin; Jacqueline DeGraaf; Patrick R Lawler; William C Cromwell; John T Wilkins; George Thanassoulis
Journal:  J Lipid Res       Date:  2018-05-16       Impact factor: 5.922

Review 10.  Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care.

Authors:  Gerald F Watts; Samuel S Gidding; Pedro Mata; Jing Pang; David R Sullivan; Shizuya Yamashita; Frederick J Raal; Raul D Santos; Kausik K Ray
Journal:  Nat Rev Cardiol       Date:  2020-01-23       Impact factor: 32.419
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.